William Blair analyst Ryan Daniels has maintained their bullish stance on ADUS stock, giving a Buy rating on November 13.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Daniels has given his Buy rating due to a combination of factors related to the recent developments in the home health payment system. The final rule for the Calendar Year 2026 Home Health Prospective Payment System represents a significant improvement over the initially proposed payment reduction. Originally, a 6.4% cut was suggested, but the finalized rule indicates a more manageable 1.3% reduction. This adjustment includes a 2.4% increase offset by various decreases, notably a smaller permanent behavior adjustment than previously proposed.
These changes are seen as favorable for home health providers like Addus Homecare, as they mitigate the financial impact of the new payment system. The overall reduction in Medicare payments is now expected to be around $220 million, which is less severe than anticipated. This improvement in the payment landscape, coupled with the company’s ability to navigate the Patient Driven Groupings Model, supports the Buy rating as it positions Addus Homecare to perform well under the updated regulations.
According to TipRanks, Daniels is a 3-star analyst with an average return of 2.6% and a 41.71% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Addus Homecare, Idexx Laboratories, and TransMedics Group.
In another report released on November 13, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $127.00 price target.